IPM Take
This is de-escalation with a practical payoff. Myeloma patients already carry systemic treatment, scans, marrow toxicity and repeated appointments. If painful uncomplicated lesions can be controlled with one or two very-low-dose radiation treatments, the value is not just less radiation. It is less disruption.
Executive Summary
At the 2026 ASTRO Annual Meeting, investigators presented a prospective multi-institutional Phase II study of 4-Gy response-adapted radiotherapy for painful uncomplicated bone lesions in multiple myeloma. The trial included 63 evaluable patients with 70 lesions across seven institutions. Patients received either a single 4-Gy fraction or two 2-Gy fractions. Per-protocol pain response was 59% at four weeks, 63% at eight weeks and 82% at six months. Only 24% required a second course of radiotherapy. There were no grade 3 or higher treatment-related toxicities.
Why it matters
- Patients / advocates: One or two treatments may be easier to integrate into already complicated myeloma care.
- Clinicians: Lower radiation dose may preserve marrow while still achieving useful pain control.
- Hospitals / providers: Shorter courses can reduce treatment burden and radiotherapy-resource use.
- Payers: Effective de-escalation can lower utilisation without automatically sacrificing outcomes.
Oncology sometimes confuses intensity with seriousness.
Multiple myeloma should teach the opposite lesson.
Patients with myeloma may already be receiving combinations of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecifics or cellular therapy. They undergo marrow monitoring, imaging and repeated hospital visits. When a painful bone lesion appears, adding another prolonged treatment course can become one burden too many.
The ASTRO data suggest that, for selected uncomplicated lesions, 4 Gy may be enough to start.
The trial used either one 4-Gy treatment or two 2-Gy treatments. Pain response improved over time, reaching 82% among evaluable patients at six months. Only about one quarter required additional radiation, and no grade 3 or higher treatment-related toxicity was observed.
That is a meaningful de-escalation signal.
The concept is also biologically sensible. Myeloma is highly radiosensitive, while bone marrow is something clinicians increasingly want to protect, particularly as modern systemic treatments already create hematologic pressure.
The clever part of the design is not merely “give less radiation.”
It is response-adapted care.
Start low. Watch the pain. Escalate only for patients who need more.
That is personalised medicine stripped of its expensive vocabulary.
The study is Phase II and single-arm, so it should not be treated as the final word. But it asks the right implementation question: why expose everyone to a larger dose when a smaller one may be sufficient for most?
Sometimes less treatment is not compromise.
It is better design.
